
Tetrous signed a new distribution agreement with Alpha Medical, which will have exclusive distribution rights in New Zealand for the Tetrous EnFix demineralized bone fiber (DBF) implants intended for enthesis repair in shoulder, elbow, hip, knee and ankle procedures.
The EnFix family of allograft products is designed to enhance healing at the enthesis, where failure often occurs. The implants are 100% DBF, providing osteoinductivity and osteoconductivity, supporting optimal biologic performance with minimal disruption to current surgical techniques.
“We are thrilled to partner with Alpha Medical, a respected medical distribution leader in New Zealand,” said John Bojanowski, Chief Commercial Officer at Tetrous. “Their experience with biologic products and their dedication to improving patient outcomes makes them the ideal partner to promote and distribute Tetrous’ products.”
Source: Tetrous, Inc.
Tetrous signed a new distribution agreement with Alpha Medical, which will have exclusive distribution rights in New Zealand for the Tetrous EnFix demineralized bone fiber (DBF) implants intended for enthesis repair in shoulder, elbow, hip, knee and ankle procedures.
The EnFix family of allograft products is designed to enhance healing at the...
Tetrous signed a new distribution agreement with Alpha Medical, which will have exclusive distribution rights in New Zealand for the Tetrous EnFix demineralized bone fiber (DBF) implants intended for enthesis repair in shoulder, elbow, hip, knee and ankle procedures.
The EnFix family of allograft products is designed to enhance healing at the enthesis, where failure often occurs. The implants are 100% DBF, providing osteoinductivity and osteoconductivity, supporting optimal biologic performance with minimal disruption to current surgical techniques.
“We are thrilled to partner with Alpha Medical, a respected medical distribution leader in New Zealand,” said John Bojanowski, Chief Commercial Officer at Tetrous. “Their experience with biologic products and their dedication to improving patient outcomes makes them the ideal partner to promote and distribute Tetrous’ products.”
Source: Tetrous, Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





